These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9055014)

  • 1. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH; Goh CL; Ang CB
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
    Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
    J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G; Malagoli P; Santagostino L
    Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
    Starace M; Vezzoni R; Alessandrini A; Bruni F; Carpanese MA; Misciali C; Sechi A; Piraccini BM
    Dermatol Ther; 2021 Sep; 34(5):e15096. PubMed ID: 34390608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of alopecia areata with squaric acid dibutylester.
    Micali G; Cicero RL; Nasca MR; Sapuppo A
    Int J Dermatol; 1996 Jan; 35(1):52-6. PubMed ID: 8838932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
    Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
    Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
    Vedak P; Kroshinsky D
    J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical immunotherapy with squaric acid dibutylester: unusual hair pigmentary changes in two cases of alopecia areata.
    Mastrolonardo M; Diaferio A
    J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):186. PubMed ID: 12046838
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis.
    Tosti A; Guidetti MS; Bardazzi F; Misciali C
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):199-201. PubMed ID: 8708020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alopecia areata: more on topical sensitizers.
    Orecchia G; Marelli MA; Perfetti L; Rabbiosi G
    Dermatologica; 1990; 180(2):57-9. PubMed ID: 2311796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation.
    Losol E; Şentürk N
    Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
    Kagami S; Kishi Y; Hino H
    J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
    Lee S; Kim BJ; Lee YB; Lee WS
    JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl.
    Chen CA; Carlberg V; Kroshinsky D
    Pediatr Dermatol; 2017 Jan; 34(1):e44-e46. PubMed ID: 27699860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months.
    van der Steen PH; Boezeman JB; Happle R
    Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.